Back to Newsroom

Cempra’s Solithromycin Demonstrates No QT Effects in Thorough QT Study

CHAPEL HILL, N.C., Feb. 11, 2014 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that solithromycin demonstrated no QT effects at single intravenous (IV) doses of 800 mg in a Thorough QT (TQT) study.